Press Release

Apexigen to Participate in Upcoming Investor Conferences

San Carlos, CA, July 8, 2021 – Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, today announced that Xiaodong Yang, M.D., Ph.D., President and Chief Executive Officer, and Linda Rubinstein, Chief Financial Officer, will participate in the following upcoming investor conferences in July:

  • William Blair Biotech Focus Conference 2021

Format: Corporate update and one-on-one investor meetings
Presentation Date & Time: Thursday, July 15, 2021, at 11:00 a.m. ET
Presentation Webcast: Click Here 

  • LifeSci Annual Summer Symposium

Format: Corporate update
Presentation Date & Time: Wednesday, July 21, 2021, at 11:30 a.m. ET
Registration: Click Here 

About Apexigen

Apexigen is a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, with an emphasis on new immuno-oncology agents that may harness the patient’s immune system to combat and eradicate cancer. Sotigalimab and Apexigen’s other programs were discovered using Apexigen’s proprietary APXiMAB™ discovery platform. This platform has enabled Apexigen and its collaboration partners to discover and develop high-quality therapeutic antibodies against a variety of molecular targets, including targets that are difficult to drug with conventional antibody technologies. Seven product or product candidates discovered using APXiMAB are currently commercially available or in clinical development, either internally by Apexigen or by its licensees. For more information, please visit www.apexigen.com.

Investor Contact:

Bruce Mackle
LifeSci Advisors
646-889-1200
bmackle@lifesciadvisors.com

Apexigen Contact:

Mark Nevins
Sr. Vice President, Business Development
Apexigen
650-931-6236
mnevins@apexigen.com